Cover Image
市場調查報告書

田邊三菱製藥 - 產品平台分析

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240931
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
田邊三菱製藥 - 產品平台分析 Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016
出版日期: 2016年09月30日 內容資訊: 英文 111 Pages
簡介

田邊三菱製藥是總公司設立於日本的製藥企業,正在從事處方藥及OTC藥的開發·製造·銷售。處方藥有自體免疫疾病,糖尿病,腎臟疾病,中樞神經系統疾病等產品,同時也正在開發疫苗。通路相當多元化,提供批發,醫院,藥局等產品。

本報告提供田邊三菱製藥的治療藥開發平台的現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

田邊三菱製藥 基本資料

  • 田邊三菱製藥 概要
  • 主要資訊
  • 企業資料

田邊三菱製藥 :R&D概要

  • 主要的治療範圍

田邊三菱製藥 :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

田邊三菱製藥 :開發中產品概況

  • 後期階段產品開發中產品
  • 臨床階段的開發中產品
  • 初期階段的開發中產品

田邊三菱製藥 :藥物簡介

  • canagliflozin
  • edaravone
  • infliximab
  • teneligliptin
  • (canagliflozin + metformin hydrochloride XR)
  • (canagliflozin + teneligliptin)
  • avanafil
  • cariprazine
  • encenicline hydrochloride
  • fingolimod hydrochloride
  • telaprevir
  • bepotastine besylate
  • masilukast
  • MIN-117
  • MT-1303
  • MT-210
  • MT-3995
  • MT-4580
  • NU-300
  • TA-7906
  • GB-1057
  • MP-124
  • MP-157
  • MT-0814
  • MT-8554
  • Antibody to Inhibit RGM for Spinal Cord Injury
  • Monoclonal Antibody for Inflammatory Disorders
  • Small Molecule to Block Sodium Channels for Ischemic Stroke
  • Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke
  • Small Molecules to Inhibit DPP-IV for Hyperglycemia
  • Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases
  • TA-3404
  • Y-320
  • Monoclonal Antibodies for Undisclosed Indication
  • Monoclonal Antibody for Cancer
  • Small Molecule to Inhibit PDE5 for Undisclosed Indication
  • Small Molecule to Inhibit S-Adenosyl-L-Homocysteine Hydrolase for Undisclosed Indication
  • T-6932

田邊三菱製藥 :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

田邊三菱製藥 :最新的開發平台資訊

田邊三菱製藥 :開發暫停中的計劃

田邊三菱製藥 :開發中止的開發中產品

開發中止的開發中產品簡介

田邊三菱製藥 :企業理念

田邊三菱製藥 :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08146CDB

Summary

Global Markets Direct's, 'Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016', provides an overview of the Mitsubishi Tanabe Pharma Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Mitsubishi Tanabe Pharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Mitsubishi Tanabe Pharma Corporation
  • The report provides overview of Mitsubishi Tanabe Pharma Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Mitsubishi Tanabe Pharma Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Mitsubishi Tanabe Pharma Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Mitsubishi Tanabe Pharma Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mitsubishi Tanabe Pharma Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitsubishi Tanabe Pharma Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Mitsubishi Tanabe Pharma Corporation Snapshot
    • Mitsubishi Tanabe Pharma Corporation Overview
    • Key Facts
  • Mitsubishi Tanabe Pharma Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Mitsubishi Tanabe Pharma Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Mitsubishi Tanabe Pharma Corporation - Pipeline Products Glance
    • Mitsubishi Tanabe Pharma Corporation - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Mitsubishi Tanabe Pharma Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Mitsubishi Tanabe Pharma Corporation - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Mitsubishi Tanabe Pharma Corporation - Drug Profiles
    • (canagliflozin + teneligliptin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amiselimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avanafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bepotastine besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canagliflozin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cariprazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edaravone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fingolimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GB-1057 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infliximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masilukast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIN-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-124 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-157 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-0814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-3995 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-4580 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-7117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-8554 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NU-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit S-Adenosyl-L-Homocysteine Hydrolase for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-6932 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TA-3404 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teneligliptin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • valbenazine tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Y-320 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mitsubishi Tanabe Pharma Corporation - Pipeline Analysis
    • Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Target
    • Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Route of Administration
    • Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Molecule Type
    • Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action
  • Mitsubishi Tanabe Pharma Corporation - Dormant Projects
  • Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AMG-899
      • AV-412
      • caldaret
      • carmoterol
      • coleneuramide
      • colestilan chloride
      • ecabet
      • edaravone
      • encenicline hydrochloride
      • fingolimod hydrochloride
      • immune globulin (human)
      • marimastat
      • masilukast
      • MP-136
      • MP-435
      • MT-7716
      • netoglitazone
      • sofigatran
      • TA-5493
      • TA-5538
      • TA-6666
      • TAK-128
      • telaprevir
      • Y-700
  • Mitsubishi Tanabe Pharma Corporation - Company Statement
  • Mitsubishi Tanabe Pharma Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Mitsubishi Tanabe Pharma Corporation, Key Facts
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Indication, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2016
  • Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2016
  • Mitsubishi Tanabe Pharma Corporation - Combination Treatment Modalities in Pipeline, 2016
  • Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2016
  • Mitsubishi Tanabe Pharma Corporation - Partnered Products/ Combination Treatment Modalities, 2016
  • Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2016
  • Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pre-Registration, 2016
  • Mitsubishi Tanabe Pharma Corporation - Phase III, 2016
  • Mitsubishi Tanabe Pharma Corporation - Phase II, 2016
  • Mitsubishi Tanabe Pharma Corporation - Phase I, 2016
  • Mitsubishi Tanabe Pharma Corporation - IND/CTA Filed, 2016
  • Mitsubishi Tanabe Pharma Corporation - Preclinical, 2016
  • Mitsubishi Tanabe Pharma Corporation - Discovery, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Target, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action, 2016
  • Mitsubishi Tanabe Pharma Corporation - Dormant Developmental Projects,2016
  • Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products, 2016
  • Mitsubishi Tanabe Pharma Corporation, Other Locations
  • Mitsubishi Tanabe Pharma Corporation, Subsidiaries

List of Figures

  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Indication, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2016
  • Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2016
  • Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2016
  • Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Target, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2016
  • Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top